PVLA logo

PALVELLA THERAPEUTICS INC

PVLANASDAQ
🏆 #1991 by market capUS Equity
$179.86▲ $14.23 (+7.91%)
Simulated price
🔔
Track PVLA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.9%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$2.01B
Small Cap
📈Revenue Growth (YoY)
-97.2%
Declining
📊Gross Margin
—
💵FCF Margin
0.4%
Thin
⚖️P/S Ratio
50.1x
Expensive
Otter Score
64
Fair
No chart data available for PVLA.

Trading Snapshot

Day Range
$178.97 – $181.78
52-Week Range
$57.33 – $161.38
Volume
$3.90B
Avg Volume
$3.84B
Shares Outstanding
14.3M
Next Earnings
Nov 16, 2026

Fundamentals Snapshot

Annual Revenue
$40M
Last Q Revenue
$10M
P/E Ratio
—
P/S Ratio
50.1x
EPS (TTM)
$-4.82
Dividend Yield
—
Dilution (1yr)
+405.5%

Why Investors Own PVLA

  • ✓High-growth profile — revenue up +20.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 69% gross margin and 16% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PVLA logo

PALVELLA THERAPEUTICS INC

PVLA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
89.3%▼ −3.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$39M▲ +173.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$25M▲ +130.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
11.3M▲ +405.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$57M▼ −$26M YoY
StockOtter · stockotter.space

About PALVELLA THERAPEUTICS INC

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$220.44
▲ +22.6% Upside
High Target$246.12
Low Target$202.14
Based on 25 analysts

Latest News & Updates

🚀
Barron’s·2h ago

PALVELLA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift PVLA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

PALVELLA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.